Friday, May 20, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home News

Unique immune cell fingerprint can help rapidly identify better treatment for autoimmune disease

by Medical Finance
in News
Unique immune cell fingerprint can help rapidly identify better treatment for autoimmune disease
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

Most autoimmune diseases are easy to diagnose but hard to treat. A paper published today in Science proposes using your unique immune cell fingerprint to rapidly identify which treatments will work for your autoimmune disease.

We analyzed the genomic profile of over one million cells from 1,000 people to identify a fingerprint linking genetic markers to diseases such as multiple sclerosis, rheumatoid arthritis, lupus, type 1 diabetes, spondylitis, inflammatory bowel disease, and Crohn’s disease. We were able to do this using single cell sequencing, a new technology that allows us to detect subtle changes in individual cells.”


Professor Joseph Powell, joint lead author, Garvan Institute of Medical Research

The discovery could help individuals find tailored treatments that work for them and guide the development of new drugs.

The study by researchers in Sydney, Hobart, Melbourne, Brisbane and San Francisco helps us understand why some treatments work well in some patients, but not in others. It’s the largest study to date to link disease-causing genes to specific types of immune cells.

A trial is now underway in Sydney with Crohn‘s disease patients to predict which treatments will work for specific patients.

‘Some autoimmune diseases can be notoriously difficult to treat,’ says Professor Powell.

‘Because of our immune system‘s complexity, and how vastly it varies between individuals, we don‘t currently have a good understanding of why a treatment works well in some people but not in others,’ he says.

The study links specific genes and immune cell types to an individual’s disease, including multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, type 1 diabetes and Crohn’s disease.

This means an individual’s unique genetic profile could be used to deliver treatments tailored to precisely tame their immune system.

‘Our data also provides a new avenue for narrowing down potential drug targets. The potential health and economic impacts of this research are enormous,’ says Professor Alex Hewitt, joint lead author and clinician-researcher at the University Of Tasmania’s Menzies Institute for Medical Research.

‘Most rare genetic diseases are like a major car accident in the body – they are generally easy to identify and locate where they occur in the genome. But immune diseases are often more like traffic congestion, where genetic changes that hold up traffic are harder to specifically pinpoint. This study has helped us identify the trouble spots,’ says Professor Hewitt.

‘The greatest insight from this work will be identification of therapeutic targets and defining sub-populations of immune disease, which can then refine clinical trials to assess drug effectiveness,’ he says.

Our bodies’ immune systems are designed to fight external threats, but autoimmune diseases occur when our immune systems take aim at our own healthy cells. They affect about one in 12 Australians, are incurable and require lifelong treatments to minimize the damage.

Often, patients will trial many different treatments before finding one that works for them.

‘Some medications may be very effective in only 15% of patients, so are not recommended as a first-line treatment,’ says Dr Seyhan Yazar, co-first author of the study.

‘We now have a way to link treatment response back to an individual’s immune genetics – and to potentially screen for that 15% of patients before a clinician even administers a treatment.’

The researchers say their data could lower the risks associated with developing new treatments.

‘Pharmaceutical companies may have hundreds of targets and have to make decisions about which they will take forward to Phase I clinical trials, knowing that 90% of potential drug candidates fail during clinical development,’ says Dr José Alquicira-Hernández, co-first author and researcher at the Garvan Institute.

‘Understanding which cell types are relevant for a particular disease is key for developing new drugs.’

A million cells reveal complexity and provide certainty

The study provides unique insights by looking at genes in individual immune cells on an unprecedented scale. It analysed the genomics of more than one million individual immune cells from around 1,000 healthy individuals, exploring 14 different types of immune cells in total.

This individual approach paints a far clearer picture than previous studies which analyzed combined cells in a blood sample.

‘The problems with bulk RNA analysis is that we only observe an averaged signal. But there is vast variation in cell functions and cell types that allow the body to defend against attack,’ explains says Dr Yazar.

‘Average analysis doesn’t reflect what happens in the full variety of immune cells.’

Integrating into clinical trials

The findings have led to clinical trials.

‘We are working on a study of Crohn‘s disease in collaboration with St George Hospital that will determine how a patient‘s immune genotype affects their response to different treatments and are looking to establish new trials in a range of autoimmune diseases’ says Professor Powell.

‘It is a significant milestone of Garvan‘s pioneering OneK1K study aimed at showing how genetics contribute to the risk of immune disease at a cellular level.’

Source:

Garvan Institute of Medical Research

Journal reference:

Yazar, S., et al. (2022) Single-cell eQTL mapping identifies cell type specific genetic control of autoimmune disease. Science. doi.org/10.1126/science.abf3041.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies

New insights into molecular mechanisms that underpin the body’s natural defenses against skin cancer

by Medical Finance
May 20, 2022
0

A study published today in Cell Reports reveals important insights into the molecular mechanisms that underpin the body's natural defenses...

Monitoring the presence of enteric pathogens in imported seafood

Monitoring the presence of enteric pathogens in imported seafood

by Medical Finance
May 20, 2022
0

To monitor the presence of enteric pathogens in imported seafood, the authors of this paper collected a total of 140...

AI-driven solution predicts RNA and DNA binding sites to accelerate rational drug discovery

AI-driven solution predicts RNA and DNA binding sites to accelerate rational drug discovery

by Medical Finance
May 20, 2022
0

The iMolecule group from Skoltech has developed an artificial intelligence-driven solution that uses data on the structure of RNA or...

Excelitas technologies introduces µPAX-3 Pulsed Xenon Light Source

Excelitas technologies introduces µPAX-3 Pulsed Xenon Light Source

by Medical Finance
May 20, 2022
0

Excelitas Technologies Corp., a leading industrial technology manufacturer focused on delivering innovative, market-driven photonic solutions, announces the new µPAX-3 Pulsed...

Uno single tube reader

High resolution single tube reader

by Medical Finance
May 20, 2022
0

From Ziath LtdJan 12 2022Reviewed by Maria Osipova Ziath announce the Uno single tube reader – a powerful device packed...

Flowmeter Solutions for High-Speed Batch Dosing

Flowmeter Solutions for High-Speed Batch Dosing

by Medical Finance
May 20, 2022
0

Titan Enterprises has published a white paper reporting on an investigation into the use of electronic flow meters in high-speed...

Next Post
Study: A virus-specific monocyte inflammatory phenotype is induced by SARS-CoV-2 at the immune–epithelial interface. Image Credit: MIA Studio/Shutterstock

Researchers investigate SARS-CoV-2 specific inflammatory response

IVM-MS2, “The most compact all-in-one IntraVital two-photon microscopy system in the world”

IVM-MS2, “The most compact all-in-one IntraVital two-photon microscopy system in the world”

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine. Image Credit: Tobias Arhelger/Shutterstock
    Comparative immunogenicity of reduced and standard BNT162b2 and mRNA-1273 boosters in CoronaVac vaccinees
  • Study: SARS-CoV-2: Mechanism of infection and emerging technologies for future prospects. Image Credit: Blue Planet Studio / Shutterstock.com
    An in-depth analysis of pathogenesis of SARS-CoV-2 and therapeutic options for COVID-19
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply